Intranasal leptin prevents opioid-induced respiratory depression

C. Freire (Baltimore, United States of America), H. Pho (Baltimore, United States of America), L. Kim (Baltimore, United States of America), X. Wang (Washington, United States of America), J. Dyavanapalli (Washington, United States of America), S. Streeter (Baltimore, United States of America), T. Fleury-Curado (Baltimore, United States of America), D. Mendelowitz (Baltimore, United States of America), V. Polotsky (Baltimore, United States of America)

Source: Virtual Congress 2020 – The impact of different treatment modalities on obstructive sleep apnoea
Session: The impact of different treatment modalities on obstructive sleep apnoea
Session type: Oral Presentation
Number: 4735

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Freire (Baltimore, United States of America), H. Pho (Baltimore, United States of America), L. Kim (Baltimore, United States of America), X. Wang (Washington, United States of America), J. Dyavanapalli (Washington, United States of America), S. Streeter (Baltimore, United States of America), T. Fleury-Curado (Baltimore, United States of America), D. Mendelowitz (Baltimore, United States of America), V. Polotsky (Baltimore, United States of America). Intranasal leptin prevents opioid-induced respiratory depression. 4735

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: